$6.00
-0.22-3.62%
Last update: Oct 30, 10:50 AM
Phathom Pharmaceuticals Inc
PHATNASDAQ
Phathom Pharmaceuticals (PHAT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Phathom Pharmaceuticals (PHAT) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided revenue in the range of $310M - $325M for the period.
Compared to prior guidance, Phathom Pharmaceuticals maintained its revenue forecast from a prior range of $310M - $325M.
Phathom Pharmaceuticals has issued 8 guidance updates between August 6, 2025 and October 29, 2026. During this period, the company raised its outlook 3 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.02 | $-0.11 | $-0.21 | $-0.19 |
| Actual | $0.04 | $0.00 | $-0.18 | $-0.08 |
| Surprise | +100.0% | +100.0% | +14.3% | +57.9% |
| Revenue | ||||
| Estimate | $85.1M | $73.6M | $56.8M | $57.4M |
| Actual | $84.7M | $74.3M | $58.3M | $57.6M |
| Surprise | -0.44% | +1.01% | +2.66% | +0.26% |
| Metric | Q4 '26E |
|---|---|
| Earnings Per Share (Non-GAAP) | |
| Consensus | $0.10 |
| Revenue | |
| Consensus | $98.4M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $0.04 | $0.02 | 100.0 % |
| Q2 | Jul 30, 2026 | $0 | $-0.11 | 100.0 % |
| Q1 | Apr 30, 2026 | $-0.18 | $-0.21 | 14.3 % |
| Q4 | Feb 26, 2026 | $-0.08 | $-0.19 | 57.9 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $84.72M | $85.10M | -0.44 % |
| Q2 | Jul 30, 2026 | $74.30M | $73.55M | 1.01 % |
| Q1 | Apr 30, 2026 | $58.30M | $56.79M | 2.66 % |
| Q4 | Feb 26, 2026 | $57.58M | $57.43M | 0.26 % |
